LONDON, Oct 10, 2011 (BUSINESS WIRE) -- Novo Nordisk has today announced the launch of their new disposable prefilled insulin pen -- FlexTouch(R) - in the UK. FlexTouch(R) is available in the UK with Novo Nordisk's rapid-acting modern insulin analogue NovoRapid(R) (insulin aspart).
FlexTouch(R) is the latest innovation within disposable prefilled insulin pens and offers a new insulin injection experience for patients with diabetes using insulin. The unique design includes a spring that allows insulin to be administered at any dose (from 1 to 80 units) with a simple touch of a button -- meaning that the device absorbs the force of the injection, setting it apart from current insulin pens. Healthcare professionals recognise the benefits that this will bring with 3 out of 4 rating FlexTouch(R) as 'very easy' to inject at 20 units(1,2).
"This new device really does offer potential advantages to patients," explained Debbie Hicks, Nurse Consultant, Diabetes, Enfield Community Services BEH-MHT, "everyone benefits when the pen is simple and easy to use -- patients, doctors and nurses educating the patients. It is really important that we continue to give our patients options in the way their treatment is delivered, so that this becomes as little an interruption to their life as we can make it."
Viggo Birch, Managing Director for Novo Nordisk Limited added, "Novo Nordisk is committed to continually improving our diabetes medicines and devices that can help solve some of the major challenges people with diabetes face every day. We are very proud to make FlexTouch(R) available to UK patients, as it is designed to benefit both patients living with diabetes and the healthcare professionals who are treating them."
EDITOR'S NOTES:
About FlexTouch(R)
FlexTouch(R) is a prefilled insulin pen containing 300 units of insulin. It doses in 1 unit increments, from 1 to 80 units. It is designed for use with both NovoTwist(R) and NovoFine(R) needles.
NovoTwist(R) comes in 5 mm (32G Tip) and 8 mm (30G) versions. An audible and tactile 'click' confirms attachment of the needle.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.co.uk.
References
1. Oyer D et al. Exp Opin Drug Delivery 2011; Sep 12.
doi 10.1517/17425247.2011.615830
2. Bailey T et al. Curr Med Res Opin 2011; 27(10):2043-2052
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50022864&lang=en
SOURCE: Novo Nordisk Limited